retatrutide for addiction vs Tirzepatide — What to Know Before You Decide VIDEO: How Can GLP-1 Agonists

The GLP-1 agonists mimic these actions, and their modified structures lead to slower elimination and a longer duration of action

The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction

The Medicare GLP1 Bridge program Starting July 1, 2026, the Medicare GLP1 Bridge provides coverage for GLP1 weight-loss medications for the first time under a temporary demonstration program

Tirzepatide and injectable semaglutide were associated with the greatest weight loss after a year of treatment among several GLP-1 receptor agonists, a recent study showed

When to Seek Urgent Medical Help or Go to the ER In most cases, constipation can be managed at home with lifestyle changes

Summary: Retatrutide is an investigational triple hormone receptor agonist peptide (GLP-1, GIP, and glucagon) developed by Eli Lilly for obesity treatment, currently in Phase 3 trials and not yet approved by the MHRA or EMA